A U.S. court found GW Pharmaceuticals did not violate a patent owned by cannabis giant Canopy Growth. The ruling, in a 2020 case brought by Canopy Growth, claimed GW, maker of the high-CBD drug Epidiolex, was handed down by a federal district court in Texas. Ontario-based Canopy Growth had alleged that GW appropriated its patented cannabis extraction method. GW Pharmaceuticals is owned by Dublin, Ireland-based Jazz Pharmaceuticals, which purchased the UK-based company last year for $7.2 billion in cash and stock. It’s not known if Canopy Growth intends to appeal the decision.
Like HempToday? How you can support us
Your donations help us to keep HempToday open for all readers, regardless of what they can afford to pay. Through this “information equality” we're able to support hemp entrepreneurs and stakeholders all over the world by keeping a spotlight on hemp and all the promise it offers for economic development and healing our planet.